Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;24(1):3-10.
doi: 10.1097/IPC.0000000000000350.

Diagnosis and Treatment of Clostridium difficile Infection (CDI)

Dale N Gerding  1   2 , Thomas M File Jr  3   4 , L Clifford McDonald  5
Affiliations

Diagnosis and Treatment of Clostridium difficile Infection (CDI)

Dale N Gerding et al. Infect Dis Clin Pract (Baltim Md). 2016 Jan.

Abstract

Early and accurate diagnosis is essential for optimal treatment of individuals with Clostridium difficile infection (CDI) and for implementation of effective infection control procedures. The decision about which diagnostic test to use is an important one that should be based on test sensitivity, specificity, and predictive value. The challenges of CDI go beyond rapid identification and management of symptomatic patients. Asymptomatic carriage has long been suspected in C. difficile transmission, but it may play a larger role than previously thought. Emerging information also shows that patients treated for CDI remain colonized for many weeks after symptom resolution. In fact, stool culture positivity increases during the first weeks following treatment completion. Treatments that reduce the duration and degree of asymptomatic shedding could have added benefit for reduced transmission.

Keywords: CDI; Clostridium difficile; diagnostic test; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosures: NFID must ensure balance, independence, objectivity, and scientific rigor in its educational activities. All individuals with control over content are required to disclose any relevant financial interest or other relationship with manufacturer(s) of any product or service discussed in an educational presentation and/or with the commercial supporters of this activity. Disclosure information is reviewed in advance to manage and resolve any conflict of interest, real or apparent, that may affect the balance and scientific integrity of an educational activity. Marla Dalton, CAE (NFID staff, content reviewer) owns stock, stock options, or bonds from Merck & Co. Inc. Thomas M. File, Jr. MD (author) served as an advisor or consultant for Astellas, Cubist, Durata, GlaxoSmithKline, Nabriva, Pfizer Inc., and Tetraphase and received grant or research support from Cempra and Pfizer Inc. Dale N. Gerding, MD (author) holds patents for the treatment and prevention of C. difficile infection licensed to ViroPharma/Shire, and is a consultant or advisory board member for Merck & Co. Inc, Cubist, Actelion Pharmaceuticals Ltd, Sanofi Pasteur, Rebiotix Inc., Da Volterra, Pfizer Inc., Summit Pharmaceuticals International, and ViroPharma/Shire.William Schaffner, MD (NFID Medical Director, content reviewer) served as an advisor or consultant for Merck & Co., Inc., Pfizer Inc., and Novavax. All other planners and content reviewers have no funding or conflicts of interest to disclose.

Figures

Figure 1
Figure 1. Predictive Value for a Theoretical Test Based on True CDI Disease Prevalence [Planche Lancet Infect Dis 2008]
Effect of varying prevalence on the PPV and NPV of a theoretical Clostridium difficile toxin assay with a sensitivity of 92% and a specificity of 97% NPV=negative predictive value. PPV=positive predictive value.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akerlund T, Persson I, Unemo M, et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol. 2008;46(4):1530–1533. - PMC - PubMed
    1. Alasmari F, Seiler SM, Hink T, et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis. 2014;59(2):216–222. - PMC - PubMed
    1. Alfa MJ, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38(7):2706–2714. - PMC - PubMed
    1. Beaulieu C, Dionne LL, Julien AS, et al. Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm. Clin Microbiol Infect. 2014;20(10):1067–1073. - PubMed
    1. CDC. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61(9):157–162. - PubMed

LinkOut - more resources